- Toll Free: +1-800-792-5285
- (UK): +44-845-528-1300
- Int'l: +1-503-894-6022
- Help@alliedmarketresearch.com
Cart
|
LI_161675
|
Pages: 143
|
Jun 2018 | 8562 Views
|
|
|
|
Author(s) :
Amrita Srivastava, & Pallavi Jaiswal
|
Tables: 52
|
Charts: 40
|
Formats*: |
|
The Global Transcatheter Aortic Valve Implantation (TAVI) Market revenue was valued at $2,761 million in 2017 and is expected to reach $8,138 million by 2025, growing at a CAGR of 13.8% from 2018 to 2025. The volume market was valued at 107,011 units in 2017 and is expected to reach 337,778 units by 2025, growing at a CAGR of 14.8% from 2018 to 2025.
Transcatheter aortic valve implantation (TAVI), also called as transcatheter aortic valve replacement (TAVR), is a minimally invasive surgical procedure, which is performed to treat high-risk patients suffering from aortic stenosis. These high-risk patients refer to the patient population that are inoperable and cannot undergo surgical aortic valve replacement (SAVR) procedure. Older population (above 75 years of age) falls under the high-risk category, as the open-heart procedure is too risky for them. TAVR involves implantation of transcatheter aortic valves to regenerate the blood circulation ability of the aortic valve. The need of transcatheter aortic valve implantation is on the rise due to the increase in prevalence of aortic stenosis.
Transcatheter aortic valve implantation (TAVI) market experiences growth due to rise in geriatric population. Furthermore, advancements in the transcatheter aortic valves and increase in adoption rate of TAVI devices drive the market. However, stringent government regulations for approval of transcatheter aortic valves, which are class III medical devices, and high cost associated with TAVI hamper the market growth. Conversely, use of TAVI systems for new indications, rise in healthcare expenditure in emerging economies, and increase in interest of key players in the global transcatheter aortic valve implantation (TAVI) industry are projected to provide several growth opportunities for the market throughout the forecast period.
Get more information on this report : Request Sample Pages
Transcatheter Aortic Valve Implantation Market Segmentation
The global transcatheter aortic valve implantation (TAVI) market is segmented based on procedure and region. According to procedure, it is classified into transfemoral implantation, transapical implantation, and transaortic implantation. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, Switzerland, the UK, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Brazil, Israel, South Africa, Saudi Arabia, and Rest of LAMEA).
Segment Review
Transcatheter aortic valve implantation procedure involves implantation of specially designed transcatheter aortic valve, which can regenerate the blood pumping function of the heart’s aortic valve. Majorly three types of approaches are used to implant these transcatheter aortic valve in the patients. These include transfemoral, transapical, and transaortic implantation. These types of implantation are differentiated based on the path chosen to place the artificial valve into its place.
Transfemoral implantation was the highest revenue generating segment in 2017 and is expected to remain so throughout the forecast period, as it is the standardized TAVI procedure, wherein artificial valve is implanted through the femoral artery with minimal anesthesia. The procedure has been accepted by majority of doctors due to its positive outcomes. Rise in prevalence of aortic stenosis coupled with increase in geriatric population drive the transcatheter aortic valve implantation (TAVI) market. In addition, increase in adoption rate for TAVI procedure and new device approvals & increased clinical evidence of effectiveness also propels the market growth. However, high cost and lack of reimbursement restrains the growth of the market. Conversely, use of TAVI systems for new indications is expected to prove as a major opportunity for the market growth.
Get more information on this report : Request Sample Pages
Snapshot of LAMEA Transcatheter Aortic Valve Implantation (TAVI) Market
Israel offers an emerging market for TAVI procedure, mainly due to increase in geriatric population and rise in demand for unmet treatment procedures. These factors propel the growth of TAVI in the Israel market. Lack of facilities and an increased need for treatment devices has drawn the major key players to invest in the Middle East market. Rapid urbanization has led to a change in lifestyle, diet, risk-prone behavior, and change in cultural attitudes of the South African population.
Hence, the occurrence of cardiac disorders is expected to increase in the coming years, which has made South Africa as one of the emerging nations that favors the growth of the transcatheter aortic valve implantation (TAVI) market. The rest of LAMEA includes Egypt, Turkey, Iran, Argentina, Colombia, and Nigeria. These regions are attracting the key players of the market due to high demand for unmet medical treatments. Moreover, rise in prevalence of aortic stenosis is the major driver for this region.
Get more information on this report : Request Sample Pages
The key players profiled in this report include Abbott Laboratories, Boston Scientific Corporation (Symetis SA), Bracco S.p.A. (HLT, Inc.), Edwards Lifesciences Corporation, JenaValve Technology, Inc., JC Medical, Inc., Medtronic plc, Meril Life Sciences Pvt. Ltd., NVT AG, and Venus Medtech, Inc.
Key Benefits
This report provides an extensive analysis of the current and emerging market trends, and dynamics in the global transcatheter aortic valve implantation (TAVI) market.
In-depth analysis is conducted by constructing market estimations for the key segments between 2017 and 2025.
This report entails the detailed quantitative analysis of the current trends and future estimations through 2017‐2025, which assists to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the growth of the transcatheter aortic valve implantation (TAVI) industry is provided.
An in-depth analysis of current research and clinical developments within the transcatheter aortic valve implantation (TAVI) market is provided.
Key players are profiled, and their strategies are analyzed thoroughly, which interprets the competitive outlook of the market.
There is an increase in demand for TAVI procedure owing to increase in prevalence of symptomatic aortic stenosis coupled with surge in population of high-risk or inoperable patients. Furthermore, the key players of the market aim to develop technologically advanced transcatheter aortic valves with increased clinical indications. Moreover, Europe is expected to dominate the global TAVI market during the forecast period, followed by North America, whereas Asia-Pacific is expected to offer lucrative opportunities to the key players in this market.
Rise in geriatric population who are prone to aortic stenosis, technological advancements in transcatheter aortic valves, and increased adoption rate of TAVI procedure are some of the major factors that drive the TAVI market. However, high cost of these devices and stringent regulatory norms of the government hamper the market growth. Currently, transfemoral implantation segment occupies the largest share in the global TAVI market, followed by transapical implantation. A majority of transcatheter aortic valve manufacturers and distributors have focused on the clinical trials to launch their technologically advanced transcatheter aortic valves.
Enterprise
License/PDF
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high level data integrity, accurate analysis and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
